This lecture consist of three parts, the first one gives a summary of mechanisms regulatting hemostasis and fibrynolysis, the second - discusses potential target molecules for therapeutic intervention, and the third one describes recent studies on selective inhibition of certain pathophysiological processes by molecules designed to prevent cardiovascular problems.Thus, a critical review of current trends in biotechnology of drugs which recently have been designed and tested to improve survival of patients with different cardiovascular diseases is provided.
Staphylokinase is a new promising therapeutic agent with an expanding clinical application in the treatment of vascular disease.In the present paper the autors discuss the biochemical and physiological properties of the recombinant protein.The methods and techniques of protein synthesis, isolation and purification, including the genetic engineering approaches are critically summarized.The emphasis is put onto the critical review of the experiments concerning the use of ataphylokinase in thrombotic models in experimental animals.Moreover, we discuss the potential role and advantages of staphylokinase over the other thrombolytic agents in the treatment of cardiovascular disease in humans.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.